TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8882994

Group type: EXPERIMENTAL
Intervention: Force Velocity Test (FVT)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Anthropometry (ALV)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Water displacement (WLV)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Total body mass
Number of subjects: 28
Study: 1303863

Group type: EXPERIMENTAL
Intervention: 4% Sodium Cromoglycate used twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2% Sodium Cromoglycate used four times daily
Number of subjects: 0
Study: 3856458

Group type: EXPERIMENTAL
Intervention: Fenfluramine (60 mg po)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Eating (after fenfluramine)
Number of subjects: 15
Study: 31393981

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 119
Study: 28660870

Group type: EXPERIMENTAL
Intervention: Global Postural Reeducation (GPR) combined with Ergonomic Verbal Advice (EVA)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Ergonomic Verbal Advice (EVA) only
Number of subjects: 19
Study: 25529830

Group type: EXPERIMENTAL
Intervention: Pregabalin (150-600 mg/day)
Number of subjects: 2747

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2747
Study: 23884013

Group type: EXPERIMENTAL
Intervention: Assisted bicycle training for 24 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no training for 24 weeks)
Number of subjects: 30
Study: 21430410

Group type: EXPERIMENTAL
Intervention: Zaltoprofen 160 mg
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Loxoprofen 60 mg
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study: 19364290

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 17919250

Group type: EXPERIMENTAL
Intervention: Flapless procedure
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional flapped procedure
Number of subjects: 12
Study: 16137016

Group type: EXPERIMENTAL
Intervention: Splenectomy plus endoscopic variceal ligation (EVL)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Pericardial devascularization (Control)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Splenectomy plus EVL
Number of subjects: 51
Study: 11317660

Group type: EXPERIMENTAL
Intervention: Inhaled insulin (AERx iDMS) at dosages of 0.3, 0.6, 1.2, and 1.8 U/kg body weight
Number of subjects: 18

Group type: COMPARATOR
Intervention: Subcutaneous insulin (0.12 U/kg body weight)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Inhaled insulin (AERx iDMS)
Number of subjects: 18
Study: 9225173

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg tid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8236144

Group type: EXPERIMENTAL
Intervention: Diltiazem (120, 240, or 360 mg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Aspirin (81 mg/day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Aspirin plus Diltiazem (81 mg/day + diltiazem)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 25

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 25
Study: 3828918

Group type: EXPERIMENTAL
Intervention: Blood collected in the Sorensen ATS Autotransfusion Receptal unit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Arterial autologous blood
Number of subjects: 0
Study: 31149881

Group type: EXPERIMENTAL
Intervention: tiletamine-zolazepam
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: alfaxalone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: propofol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: ketamine-diazepam
Number of subjects: 6
Study: 28793958

Group type: EXPERIMENTAL
Intervention: Amisulpride (200 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional formulation of amisulpride
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 20
Study: 25713002

Group type: EXPERIMENTAL
Intervention: gammaCore (noninvasive vagus nerve stimulator)
Number of subjects: 19
Study: 23622906

Group type: EXPERIMENTAL
Intervention: BioFreedom drug-coated stent
Number of subjects: 2456

Group type: COMPARATOR
Intervention: Gazelle bare metal stent
Number of subjects: 2456
Study: 20728093

Group type: EXPERIMENTAL
Intervention: 4× above the seizure threshold (ST)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 7× above the seizure threshold (ST)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 10× above the seizure threshold (ST)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: High dose intensity groups
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 4×, 7×, and 10× above ST
Number of subjects: 41
Study: 16401468

Group type: EXPERIMENTAL
Intervention: Rofecoxib (25 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15364856

Group type: EXPERIMENTAL
Intervention: FloWatch-PAB
Number of subjects: 13
Study: 11391165

Group type: EXPERIMENTAL
Intervention: 800-mg amprenavir (APV) combined with 800-mg indinavir (IDV)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 800-mg amprenavir (APV) combined with 750-mg nelfinavir (NFV)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 800-mg amprenavir (APV) combined with 800-mg saquinavir-Soft Gel Capsule (SGV-SGC)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: APV given alone for 3 weeks and then with 150-mg lamivudine (3TC) and 300-mg zidovudine (ZDV)
Number of subjects: 48
Study: 10087435

Group type: EXPERIMENTAL
Intervention: SK+heparin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: rt-PA+heparin
Number of subjects: 90

Group type: COMPARATOR
Intervention: heparin alone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: SK and rt-PA
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High-dose intravenous heparin
Number of subjects: 90
Study: 8149437

Group type: EXPERIMENTAL
Intervention: Balloon-expandable intracoronary stenting in patients with stable angina (n = 57)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Balloon-expandable intracoronary stenting in patients with unstable angina (n = 48)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Balloon-expandable intracoronary stenting
Number of subjects: 105
Study: 3408846

Group type: EXPERIMENTAL
Intervention: Ioxaglate (Hexabrix)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iopamidol (Niopam)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iohexol (Omnipaque)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (other contrast media)
Number of subjects: 0
Study: 31678507

Group type: EXPERIMENTAL
Intervention: Planned Cesarean Delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Planned Vaginal Delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous Cesarean Delivery
Number of subjects: 0
Study: 29278871

Group type: EXPERIMENTAL
Intervention: Traditional dysphagia therapy (TDT) + surface neuromuscular electrical stimulation (sNMES) in treatment group A (TGA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Traditional dysphagia therapy (TDT) + surface neuromuscular electrical stimulation (sNMES) in treatment group B (TGB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (traditional dysphagia therapy only)
Number of subjects: 30
Study: 27627126

Group type: EXPERIMENTAL
Intervention: Benson relaxation technique applied for five days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study: 25524960

Group type: EXPERIMENTAL
Intervention: Training programme for nurses
Number of subjects: 35
Study: 23254482

Group type: EXPERIMENTAL
Intervention: G-Cog power meter
Number of subjects: 0

Group type: COMPARATOR
Intervention: SRM and PowerTap devices
Number of subjects: 0
Study: 21483400

Group type: EXPERIMENTAL
Intervention: Digerfast (medical device)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Domperidone (Peridon)
Number of subjects: 36
Study: 18727842

Group type: EXPERIMENTAL
Intervention: 21 mg/24-h nicotine patch
Number of subjects: 346

Group type: COMPARATOR
Intervention: 15 mg/16-h nicotine patch
Number of subjects: 346

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 346
Study: 16505657

Group type: EXPERIMENTAL
Intervention: Fenoldopam (0.1 microg/kg/min)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dopamine (2 microg/kg/min)
Number of subjects: 100
Study: 14633745

Group type: EXPERIMENTAL
Intervention: Isocapnic hyperpnoea
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (assisted spontaneous ventilation)
Number of subjects: 14
Study: 11104115

Group type: EXPERIMENTAL
Intervention: Brief intervention counseling (7 sessions)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Brief intervention counseling (3 sessions)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Minimal advice (Control group)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 118
Study: 8761582

Group type: EXPERIMENTAL
Intervention: 3-day Quinimax treatment (25 mg/kg daily in 3 doses)
Number of subjects: 72

Group type: COMPARATOR
Intervention: 7-day Quinimax treatment (25 mg/kg daily in 3 doses)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 3-day Quinimax treatment
Number of subjects: 72
Study: 2328746

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg b.d. for one week
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.d. for one week
Number of subjects: 30
Study: 7016264

Group type: EXPERIMENTAL
Intervention: Lidocaine hydrocarbonate with epinephrine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lidocaine hydrocarbonate without epinephrine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride with epinephrine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride without epinephrine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lidocaine hydrocarbonate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lidocaine hydrochloride
Number of subjects: 100
Study: 30561570

Group type: EXPERIMENTAL
Intervention: CT scans of lymph nodes
Number of subjects: 426
Study: 28652290

Group type: EXPERIMENTAL
Intervention: Duloxetine (30 mg for 2 weeks, then 60 mg for 4 weeks)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 26385214

Group type: EXPERIMENTAL
Intervention: Severely obese patients (BMI ≥ 40)
Number of subjects: 3754

Group type: COMPARATOR
Intervention: Moderately obese, slightly obese, and overweight patients
Number of subjects: 3754

Group type: EXPERIMENTAL
Intervention: Triple-negative breast cancer patients
Number of subjects: 3754

Group type: COMPARATOR
Intervention: Other tumor subtypes
Number of subjects: 3754
Study: 22698840

Group type: EXPERIMENTAL
Intervention: Jaw relaxation for 20 min before dressing changes
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no jaw relaxation)
Number of subjects: 100
Study: 21651805

Group type: EXPERIMENTAL
Intervention: 12 week exercise intervention (the HOPE programme)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 19188077

Group type: EXPERIMENTAL
Intervention: Rewarming to a nasopharyngeal temperature of 33 degrees C (Group 1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Rewarming to a nasopharyngeal temperature of 37 degrees C (Group 2)
Number of subjects: 80
Study: 16780624

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) and dynamic bracing
Number of subjects: 24

Group type: COMPARATOR
Intervention: Neuromuscular electrical stimulation (NMES) alone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Dynamic bracing alone
Number of subjects: 24
Study: 15113316

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg once-daily for 5-14 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clarithromycin 500 mg twice-daily for 5-14 days
Number of subjects: 0
Study: 11205428

Group type: EXPERIMENTAL
Intervention: Nicotine-containing cigarette
Number of subjects: 40

Group type: COMPARATOR
Intervention: Denicotinized cigarette
Number of subjects: 40
Study: 9505889

Group type: EXPERIMENTAL
Intervention: Metal stent for patients with an inoperable tumour smaller than 30 mm
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Plastic stent for patients with a tumour greater than 30 mm
Number of subjects: 101
Study: 8174528

Group type: EXPERIMENTAL
Intervention: Nifedipine (200 micrograms added to St. Thomas' cardioplegia)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (added to St. Thomas' cardioplegia)
Number of subjects: 24
Study: 3286129

Group type: EXPERIMENTAL
Intervention: Tizanidine
Number of subjects: 105

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 105
Study: 30449852

Group type: EXPERIMENTAL
Intervention: Discontinue artificial hydration and nutrition for terminal stage patients who could no longer communicate
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Continue artificial hydration and nutrition for bedridden patients with tendency to self-remove tubes
Number of subjects: 500

Group type: COMPARATOR
Intervention: Physicians working in hospitals
Number of subjects: 500

Group type: COMPARATOR
Intervention: Physicians working in private clinics
Number of subjects: 500
Study: 27597731

Group type: EXPERIMENTAL
Intervention: Target range of 85%-89% oxygen saturation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Target range of 91%-95% oxygen saturation
Number of subjects: 0
Study: 25322274

Group type: EXPERIMENTAL
Intervention: 1,000 mg Resveratrol (RSV(high))
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 150 mg Resveratrol (RSV(low))
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 23128667

Group type: EXPERIMENTAL
Intervention: PT-led exercise
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: FI-led exercise
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 314

Group type: COMPARATOR
Intervention: Control
Number of subjects: 314
Study: 20653352

Group type: EXPERIMENTAL
Intervention: Ongoing follow‐up by the pharmacist (follow‐up group)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Return to usual care (single‐contact group)
Number of subjects: 176
Study: 18977721

Group type: EXPERIMENTAL
Intervention: efavirenz (EFV)
Number of subjects: 228

Group type: COMPARATOR
Intervention: nevirapine (NVP)
Number of subjects: 228
Study: 17283932

Group type: EXPERIMENTAL
Intervention: Color transients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Luminance transients
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-transient condition
Number of subjects: 0
Study: 12945072

Group type: EXPERIMENTAL
Intervention: Diathermy smoke extraction system (group 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard diathermy equipment (group 1)
Number of subjects: 30
Study: 10742365

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8771642

Group type: EXPERIMENTAL
Intervention: Psychosocial support intervention during pregnancy (four to six home visits providing emotional support, counseling, and strengthening of the woman's social network)
Number of subjects: 2235

Group type: EXPERIMENTAL
Intervention: Psychosocial support intervention during pregnancy
Number of subjects: 2235
Study: 1589237

Group type: EXPERIMENTAL
Intervention: Aspirin (1200 mg in effervescent solution)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (identically tasting solution without aspirin)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Aspirin and Placebo
Number of subjects: 60
Study: 3755052

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg oral dose)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sucralfate (four times a day for 2 days prior to cimetidine ingestion)
Number of subjects: 6
Study: 31514562

Group type: EXPERIMENTAL
Intervention: Balanced ultrafiltration
Number of subjects: 74

Group type: COMPARATOR
Intervention: Conventional techniques (control)
Number of subjects: 74
Study: 29616454

Group type: EXPERIMENTAL
Intervention: Social exclusion
Number of subjects: 81

Group type: COMPARATOR
Intervention: Social inclusion
Number of subjects: 81
Study: 27085322

Group type: EXPERIMENTAL
Intervention: LLLT + OM exercises
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Orofacial myofunctional therapy (OMT) + OM exercises
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: LLLT placebo + OM exercises
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: LLLT
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (GC)
Number of subjects: 82
Study: 23991748

Group type: EXPERIMENTAL
Intervention: GeneXpert MRSA performed after S. aureus identification
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control group with antibiotic susceptibility testing after MALDI‐TOF MS identification
Number of subjects: 197
Study: 23550669

Group type: COMPARATOR
Intervention: Continuous androgen deprivation
Number of subjects: 1535

Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation
Number of subjects: 1535
Study: 20610466

Group type: EXPERIMENTAL
Intervention: Antihypertensive medication adherence
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Patients' beliefs about hypertension and treatment
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Concordance with medical model
Number of subjects: 230
Study: 18097174

Group type: EXPERIMENTAL
Intervention: AcrySof ReSTOR multifocal intraocular lens (IOL)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Monofocal IOLs (Control)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: AcrySof ReSTOR multifocal IOL
Number of subjects: 38
Study: 16409337

Group type: EXPERIMENTAL
Intervention: Facemask
Number of subjects: 27

Group type: COMPARATOR
Intervention: Mouthpiece
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both facemask and mouthpiece
Number of subjects: 27
Study: 12525508

Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate (MTX) for CNS2 and TLP+ patients
Number of subjects: 2021

Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate (MTX) and cranial irradiation (18 Gy) for CNS3 patients
Number of subjects: 2021

Group type: EXPERIMENTAL
Intervention: TLP+ status
Number of subjects: 2021

Group type: COMPARATOR
Intervention: CNS1 status
Number of subjects: 2021

Group type: COMPARATOR
Intervention: CNS2 status
Number of subjects: 2021

Group type: COMPARATOR
Intervention: CNS3 status
Number of subjects: 2021

Group type: COMPARATOR
Intervention: CNS1
Number of subjects: 2021

Group type: COMPARATOR
Intervention: CNS2
Number of subjects: 2021
Study: 10731270

Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (no abciximab)
Number of subjects: 120
Study: 8857989

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (15 mmol/L) in the cardioplegic solution (group 1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No magnesium sulfate in the cardioplegic solution (group 2)
Number of subjects: 50
Study: 1320540

Group type: EXPERIMENTAL
Intervention: Candoxatril (10-200 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Exogenous infusion of synthetic human atrial natriuretic peptide (45-90 micrograms)
Number of subjects: 7
Study: 6407290

Group type: EXPERIMENTAL
Intervention: Zaditen
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Intal
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combination of Zaditen and Intal
Number of subjects: 28

Group type: COMPARATOR
Intervention: Zaditen or Intal
Number of subjects: 28
Study: 30856236

Group type: EXPERIMENTAL
Intervention: Aggressive BP reduction (target SBP <150 mmHg, n = 27)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Conservative BP reduction (target SBP <180 mmHg, n = 25)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Comparison of SBP between aggressive and conservative groups
Number of subjects: 71

Group type: COMPARATOR
Intervention: Comparison of mean rTmax between aggressive and conservative groups
Number of subjects: 71
Study: 30316737

Group type: EXPERIMENTAL
Intervention: Continuous Aerobic Training (CAT)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Intermittent Aerobic Training (IAT)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Both CAT and IAT groups
Number of subjects: 69
Study: 26861922

Group type: EXPERIMENTAL
Intervention: Text message support for weight loss (adapted from DPP curriculum for 12 months)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group (invitation to DPP classes only)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Text message support for weight loss
Number of subjects: 163
Study: 24180595

Group type: EXPERIMENTAL
Intervention: SCIT + vitamin D (650 U/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SCIT alone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 50
Study: 22706859

Group type: EXPERIMENTAL
Intervention: HPV testing (Hybrid Capture 2 assay, Qiagen)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Repeat cytology
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 560
Study: 20444958

Group type: EXPERIMENTAL
Intervention: Iron-fortified food product (total dose = 56 mg Fe/d), consumed twice daily during the 9-week BCT course.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo, consumed twice daily during the 9-week BCT course.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iron-deficient anemic soldiers (subgroup of intervention group).
Number of subjects: 0
Study: 18387338

Group type: EXPERIMENTAL
Intervention: SICI using PA-directed currents
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: SICI using AP-directed currents
Number of subjects: 29
Study: 15712083

Group type: EXPERIMENTAL
Intervention: Continuous therapy
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: CD4 cell count-guided therapy
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Week-on/week-off (WOWO) therapy
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: All therapy arms
Number of subjects: 74
Study: 12001824

Group type: EXPERIMENTAL
Intervention: 1% N-acetylcarnosine (NAC) solution, topical eyedrops twice daily
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo eyedrops
Number of subjects: 49

Group type: COMPARATOR
Intervention: No eyedrops
Number of subjects: 49